EZEE
Main information
- Trade name:
- EZEE 10 TAB
- Active ingredient:
- EZETIMIBE
- Available from:
- HETERO HC.
- Dosage:
- 10MG
- Pharmaceutical form:
- TAB
- Composition:
- 10
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
17-12-2018
Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance
Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance
Europe - EMA - European Medicines Agency
26-7-2018
Opinion/decision on a Paediatric investigation plan (PIP): Zenon, Suvezen, Ezetimibe / rosuvastatin, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
19-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Rosuvastatin / ezetimibe, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
13-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Atorvastatin,Ezetimibe, decision type: , therapeutic area: , PIP number: P/0374/2018
Opinion/decision on a Paediatric investigation plan (PIP): Atorvastatin,Ezetimibe, decision type: , therapeutic area: , PIP number: P/0374/2018
Europe - EMA - European Medicines Agency
17-12-2018
Ezetimibe product-specific bioequivalence guidance
Ezetimibe product-specific bioequivalence guidance
Europe - EMA - European Medicines Agency